<DOC>
	<DOCNO>NCT00146120</DOCNO>
	<brief_summary>The concept investigator risk-adapted multicenter treatment trial young adult , AML HD98A , base result AML HD93 trial publish data . Definition risk group different compare AML HD93 trial ; high-risk : refractory disease first induction therapy and/or high risk karyotype [ abn ( 3q ) , -5/5q- , -7/7q- , abn ( 12p ) , abn ( 17p ) , complex ] ; intermediate-risk : complete remission induction therapy intermediate risk karyotype [ normal , abn ( 11q23 ) , abn ( 16q22 ) , rare aberration ] ; low-risk : complete remission induction therapy low risk karyotype [ ( 8 ; 21 ) ] . Patients exhibit ( 15 ; 17 ) treat separated trial ( APL HD95 ) . Treatment consist first induction therapy ICE follow second cycle ICE case response first induction therapy . Patients refractory disease first induction therapy assign salvage therapy A-HAM ( all-trans retinoic acid , high-dose cytarabine mitoxantrone ) search potential hematopoietic stem cell donor extend family unrelated person . All patient achieve CR induction therapy ICE assign first consolidation therapy HAM . For intermediate-risk patient peripheral stem cell bone marrow harvest intend hematological recovery first consolidation . Second consolidation therapy stratify accord risk definition . For high risk patient allogeneic transplantation assign related unrelated donor preferentially dose-intensified conditioning therapy . All patient intermediate risk HLA-matched family donor assign allogeneic transplantation . Intermediate-risk patient without family donor normal karyotype diagnosis randomize autologous stem cell transplantation second course HAM . The intermediate-risk patient assign autologous transplantation . For low-risk patient second course HAM assign .</brief_summary>
	<brief_title>Risk-Adapted Therapy Acute Myeloid Leukemia Adults ( 18-60 Years ) According Cytogenetic Result</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Patients AML , de Novo secondary Myelodysplasy , therapyinduced AML heal primary malignom ; refractory anemia excess blast transformation ( RAEBt ) ; diagnosis must confirm morphological , cytochemical immunological phenotyping Cytogenetical test must perform patient Age : 16 60 year All patient inform character study . Written informed consent patient study entry . Organic insufficiency : Insufficiency kidney ( Crea &gt; 1.5 x upper normal serum level ) , insufficiency liver ( bilirubin , SGOT AP &gt; 2 x upper normal serum level ) uncaused AML ; severe obstruction restrictive ventilation disorder , heart failure ejection fraction &lt; 0.5 Secondary malignom Other severe disease Pregnancy Participation concurrent clinical study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>